Development of membrane-targeting TPP+-chloramphenicol conjugates to combat methicillin-resistant staphylococcus aureus (MRSA) infections
作者:Tao Li、Xiaoli He、Wenlan Tao、Ruixue Zhang、Qiaolin He、Hongzhi Gong、Ye Liu、Dong Luo、Maojie Zhang、Cheng Zou、Shao-Lin Zhang、Yun He
DOI:10.1016/j.ejmech.2023.115973
日期:2024.1
isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values ranging from 1 to 2 μg/mL, while CL was inactive to the tested MRSA strains. In addition, these conjugates exhibited rapid bactericidal properties and low toxicity, and did not readily induced bacterial resistance, obviously outperforming the parent drug CL. In a mouse model infected with a clinically isolated MRSA strain, compound
耐药菌引起的感染已成为感染治疗的新挑战,严重危害公众健康。氯霉素(CL)是一种众所周知的抗生素,但由于细菌耐药性而失去了功效。为了解决这个问题,我们在此报告了新型三苯基磷氯霉素缀合物(TPP + -CL)的设计、合成和生物学评价。研究结果表明,化合物39和42对临床分离的耐甲氧西林金黄色葡萄球菌(MRSA)具有显着的抗菌作用,MIC值在1~2 μg/mL之间,而CL对受试MRSA菌株无活性。此外,这些缀合物表现出快速杀菌特性和低毒性,并且不易诱导细菌耐药性,明显优于母药CL。在感染临床分离的MRSA菌株的小鼠模型中,20mg/kg剂量的化合物39表现出与金标准药物万古霉素相当甚至更好的体内抗MRSA功效,同时未观察到毒性。